Results 231 to 240 of about 458,313 (258)

Relapsing polychondritis

Joint Bone Spine, 2022
Yu-Tso, Li, Hsien-Tzung, Liao
openaire   +2 more sources

Pathogenic UBA1 variants define a subset of relapsing polychondritis

Nature Reviews Rheumatology, 2021
J. McHugh
semanticscholar   +1 more source

A case of VEXAS Syndrome manifesting as Kikuchi-Fujimoto Disease, Relapsing Polychondritis, Venous Thromboembolism and Macrocytic Anaemia.

Rheumatology, 2021
S. Lee, B. Fan, J. H. Lim, L. Goh, J. Lee, L. W. Koh   +5 more
semanticscholar   +1 more source

VEXAS syndrome: relapsing polychondritis and myelodysplastic syndrome with associated immunoglobulin A vasculitis.

Rheumatology, 2021
A. Pàmies, P. Ferras, Naya Bellaubí-Pallarés, T. Giménez, A. Raventós, R. Colobran   +5 more
semanticscholar   +1 more source

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

Lancet, The, 1998
George C Ebers
exaly  

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Lancet, The, 2012
Alasdair J Coles, Douglas L Arnold, Jeffrey A Cohen   +2 more
exaly  

Relapsing Polychondritis

New England Journal of Medicine, 1960
C M, PEARSON, H M, KLINE, V D, NEWCOMER
openaire   +2 more sources

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet, The, 2012
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold   +2 more
exaly  

Relapsing Polychondritis

International Journal of Dermatology, 1986
P R, Cohen, R P, Rapini
openaire   +2 more sources

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Lancet, The, 2011
Ludwig Kappos, Peter A Calabresi, Amit Bar-or   +2 more
exaly